Clariant Opens New Innovation Center in Frankfurt - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Clariant Opens New Innovation Center in Frankfurt



Untitled Document

Clariant, a provider of fine and specialty chemicals, has opened its new EUR 100 million ($134 million) Clariant Innovation Center (CIC) in Frankfurt, Germany. The company’s new global hub for R&D is based at the “Industriepark Höchst.” It will be the home of Clariant’s competence centers in chemical research and process technology as well as application laboratories for several business units and analytical laboratories. The CIC will also house the departments for Intellectual Property Management and New Business Development. As the corporation’s global hub, the CIC will coordinate Clariant’s R&D network, which includes centers across Europe, North America, Brazil, Japan, India, and China. The new facility covers a total surface area of 36,000 m2 and will house around 500 employees from R&D and support business and administrative functions. It features a mix of open workspaces, offices, and laboratories.

Source: Clariant

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here